Objective

The objective of the present study was to evaluate the serum levels of soluble oncostatin M (OSM), OSM receptor (sOSMR) and glycoprotein130 (sgp130) in patients with systemic sclerosis (SSc), and the possible associations and correlations with clinical parameters.

Methods

Serum levels of OSM, sOSMR and sgp130 were evaluated by ELISA in eighty-four SSc patients and eighty-four healthy volunteers.

Results

SSc patients had significantly elevated levels of sOSMR and sgp130 when compared with healthy individuals (p < 0.0001 and p = 0.025, respectively). Diffuse cutaneous SSc and limited cutaneous SSc patients also presented higher levels of sOSMR when compared with healthy individuals (p = 0.003 and p = 0.0001, respectively). Patients with digital ulcers presented higher levels of sOSMR when compared to those without ulcers (p = 0.034). However, sOSMR levels were lower in patients with esophageal dysfunction than patients without this involvement (p = 0.038). OSM levels were undetectable in serum from SSc patients and healthy volunteers.

Conclusion

Serum levels of sOSMR and sgp130 are elevated in patients with systemic sclerosis. In addition, associations were observed with important clinical manifestations, suggesting that sOSMR is a candidate biomarker of this disease. More studies are needed to clarify the functions of IL-6 family cytokines in systemic sclerosis.

中文翻译：

---

系统性硬化症患者可溶性制瘤素 M 受体 (sOSMR) 和糖蛋白 130 (sgp130) 水平升高以及与临床参数的关联。

客观的

本研究的目的是评估系统性硬化症 (SSc) 患者血清可溶性制瘤素 M (OSM)、OSM 受体 (sOSMR) 和糖蛋白 130 (sgp130) 的水平，以及可能与临床参数的关联和相关性。

方法

通过 ELISA 在八十四名 SSc 患者和八十四名健康志愿者中评估了 OSM、sOSMR 和 sgp130 的血清水平。

结果

与健康个体相比，SSc 患者的 sOSMR 和 sgp130 水平显着升高（分别为 p < 0.0001 和 p = 0.025）。与健康个体相比，弥漫性皮肤 SSc 和局限性皮肤 SSc 患者的 sOSMR 水平也更高（分别为 p = 0.003 和 p = 0.0001）。与没有溃疡的患者相比，有手指溃疡的患者的 sOSMR 水平更高（p = 0.034）。然而，食管功能障碍患者的 sOSMR 水平低于没有这种参与的患者（p = 0.038）。在 SSc 患者和健康志愿者的血清中无法检测到 OSM 水平。

结论

系统性硬化症患者的血清 sOSMR 和 sgp130 水平升高。此外，观察到与重要临床表现的关联，表明 sOSMR 是该疾病的候选生物标志物。需要更多的研究来阐明 IL-6 家族细胞因子在系统性硬化症中的功能。